Boston's resTORbio Sets Terms for $85M IPO Post author:Sam Post published:January 16, 2018 Post category:BioPharma resTORbio is developing novel therapies to improve immune function in the elderly. Source: BioSpace You Might Also Like Sanofi R&D Boss Thinks His Team is Ready to Survive Without Besties Regeneron and Alnylam September 20, 2017 Argentum And Eli Lilly Settle Patent Dispute Over CIALIS August 22, 2017 Pharma Giant Merck & Co. Considering 600-Job IT Hub in Austin April 5, 2017
Sanofi R&D Boss Thinks His Team is Ready to Survive Without Besties Regeneron and Alnylam September 20, 2017
